Related Experiment Video
Updated: Jun 6, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death
1Cancer Signaling Laboratory, Department of Clinical Oncology, State Key Laboratory of Oncology in South China, Sir YK Pao Center for Cancer, Chinese University of Hong Kong, Hong Kong, China.
Abstract:
c-Met represents an important emerging therapeutic target in cancer. In this study, we demonstrate the mechanism by which c-Met tyrosine kinase inhibition inhibits tumor growth in a highly invasive Asian-prevalent head and neck cancer, nasopharyngeal cancer (NPC). c-Met tyrosine kinase inhibitors (TKIs; AM7 and c-Met TKI tool compound SU11274) downregulated c-Met phosphorylation, resulting in marked inhibition of NPC cell growth and invasion. Strikingly, inhibition of c-Met resulted in significant downregulation of TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) and subsequent depletion of intracellular NADPH. Importantly, overexpression of TIGAR ameliorated the effects of c-Met kinase inhibition, confirming the importance of TIGAR downregulation in the growth inhibitory activity of c-Met TKI. The effects of c-Met inhibition on TIGAR and NADPH levels were observed with two different c-Met TKIs (AM7 and SU11274) and with multiple cell lines. As NADPH provides a crucial reducing power required for cell survival and proliferation, our findings reveal a novel mechanistic action of c-Met TKI, which may represent a key effect of c-Met kinase inhibition. Our data provide the first evidence linking c-Met, TIGAR and NADPH regulation in human cancer cells suggesting that inhibition of a tyrosine kinase/TIGAR/NADPH cascade may have therapeutic applicability in human cancers.
Insights
c-Met tyrosine kinase inhibitors (TKIs) reduce nasopharyngeal cancer growth by downregulating TIGAR and depleting NADPH. This reveals a new therapeutic pathway targeting the tyrosine kinase/TIGAR/NADPH cascade in cancers.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- c-Met is a key therapeutic target in various cancers.
- Nasopharyngeal cancer (NPC) is an invasive head and neck cancer prevalent in Asia.
- Understanding c-Met's mechanism in NPC is crucial for targeted therapy.
Purpose of the Study:
- To elucidate the mechanism by which c-Met tyrosine kinase inhibition affects NPC growth and invasion.
- To identify downstream targets of c-Met inhibition in NPC.
- To explore the therapeutic potential of targeting the c-Met pathway in NPC.
Main Methods:
- Utilized c-Met tyrosine kinase inhibitors (TKIs), AM7 and SU11274, in NPC cell lines.
- Assessed c-Met phosphorylation, cell growth, invasion, TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) expression, and intracellular NADPH levels.
- Investigated the effect of TIGAR overexpression on c-Met TKI-induced inhibition.
Main Results:
- c-Met TKIs significantly downregulated c-Met phosphorylation, NPC cell growth, and invasion.
- Inhibition of c-Met led to decreased TIGAR expression and subsequent depletion of intracellular NADPH.
- Overexpression of TIGAR counteracted the inhibitory effects of c-Met kinase inhibition, confirming TIGAR's role.
Conclusions:
- c-Met kinase inhibition impacts NPC via downregulation of TIGAR and subsequent NADPH depletion.
- This study reveals a novel tyrosine kinase/TIGAR/NADPH signaling cascade.
- Targeting this cascade presents a potential therapeutic strategy for human cancers, including NPC.
Related Concept Videos
TGF - β Signaling Pathway
Inhibition of Cdk Activity
Inhibition of CDK Activity
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
Abnormal Proliferation

